China Tops U.S. In Healthcare Expansion Destination But Regulatory Burdens Weigh – Survey
This article was originally published in PharmAsia News
Despite a deepening economic slowdown and ongoing market access challenges, China overtook the U.S. as the top destination for expansion in a survey of global healthcare executives. Meanwhile, the 300-plus executives surveyed by UPS also rank regulatory hurdles above cost as the top barrier to expansion.
You may also be interested in...
China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals
SHANGHAI - For years, China has talked about revising its drug review system to improve efficiency, and now major changes are in the works with China's State FDA reforming its drug review body, the Center for Drug Evaluation, to encourage drug innovation and facilitate globalization of its drug review process
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.